A Medical Intelligence Platform for Acupuncture Insomnia Efficacy and Mechanism Research | QSevidence 2026
Acupuncture research in insomnia needs to separate changes in sleep experience, the treatment being compared and the meaning of biological findings.
A Medical Intelligence Platform for Acupuncture Insomnia Efficacy and Mechanism Research | QSevidence 2026
QSevidence supports literature retrieval, evidence comparison and source tracing for sleep medicine, acupuncture and statistical teams examining these questions.
Start with evidence classification rather than a predetermined conclusion
The proposed systematic review centers on randomized trials in adults with insomnia. It considers manual, electro-, auricular and warm-needle acupuncture, while discussing neurotransmitter, stress-axis and brain-network studies separately. A Medical intelligence platform can connect clinical comparisons, methods and biological interpretation through traceable sources. Reliable conclusions still depend on the quality of the original studies and reproducible data.
The research narrative provides a count of 26 trials and several pooled statistics, but no complete inclusion list, search cutoff, study-level extraction table, registration identifier or statistical output. This article uses those statements to examine design and verification needs. It treats the numbers as awaiting independent confirmation and does not invent registration or completed appraisal procedures.
Specify participants and comparator questions before synthesis
The intended population is adults aged 18 or older diagnosed using relevant ICSD-3 or DSM-5 criteria. The narrative limits eligibility to primary insomnia and excludes secondary insomnia. Retrieval should retain the terminology used in each original report and clarify the handling of comorbidities, medication use, duration and baseline severity. These conditions determine applicability; people reporting poor sleep do not form a single interchangeable population.
A minimum treatment duration of two weeks is proposed, but session frequency, session length and assessment times still require extraction. Acupuncture alone and acupuncture added to shared background care answer different questions. Differences in medication, behavioral interventions or rescue treatment need documentation. The stimulation methods also need explicit definitions rather than an undifferentiated acupuncture label.
| Comparison | Question | Details to retain |
|---|---|---|
| Acupuncture versus sham | Effect relative to a specified simulated procedure | Penetration, shallow-needle location, stimulation, expectations and blinding assessment |
| Acupuncture versus medication | Benefits and burdens of different treatment strategies | Drug, regimen, duration and adverse-event ascertainment in both groups |
| Acupuncture versus behavioral therapy | Effect relative to a particular behavioral program | Whether full CBT-I was delivered, provider, contact time and adherence |
| Acupuncture versus waiting or no additional care | Overall effect of offering the service | Attention, expectations and shared interventions |
Sham acupuncture is not necessarily physiologically inert, while a waiting comparator does not control treatment contact well. Define the clinical meaning of each contrast before deciding whether pooling is appropriate. An advantage against one comparator does not establish superiority over every available treatment.
Align sleep outcomes by timing and unit
The proposed primary outcome is change in Pittsburgh Sleep Quality Index (PSQI) total score. Secondary outcomes include sleep-onset latency, total sleep time, sleep efficiency, nocturnal awakenings, Insomnia Severity Index (ISI), quality of life and adverse events. Extraction should retain the instrument, score direction, end-of-treatment time and later follow-up, distinguishing diaries and self-reports from objective measurements such as polysomnography.
PSQI and ISI assess different constructs and should not be combined simply because both concern sleep. A common scale may favor a mean difference; a standardized mean difference requires an explicit denominator and direction. An SMD is dimensionless: -1.34 is not a 1.34-point PSQI reduction, nor does it itself demonstrate that a population-specific minimum important difference has been exceeded.
Audit the numerical account of 26 trials
The narrative lists 26 randomized trials and a primary pooled SMD of -1.34, with a 95% confidence interval from -1.66 to -1.01 and P<0.001. It also describes increased total sleep time, fewer awakenings and improvements in latency and efficiency. These statements require study-level checks of sample sizes, means, standard deviations, change scores and assessment times. Reproducible inputs have not been supplied, so the numbers remain subject to original-study and output verification.
The safety account gives an adverse-event rate of 1.7%, mainly local pain and bruising, and states that related serious events were not reported. Verification requires numerators, denominators, whether rates refer to patients or sessions, active versus passive ascertainment, loss to follow-up and observation duration in each arm. Lack of reported serious events does not exclude serious risk or establish a safety advantage over medication.
Heterogeneity is described only as I²>50%, without an exact value. Sensitivity analysis is said to preserve the direction and significance after excluding high-risk studies. The reported Egger test is t=-0.61, P=0.5565. Each analysis needs its actual study count, model and outcome checked. A nonsignificant test does not establish absence of selective publication; possible small-study effects for secondary outcomes warrant separate discussion.
Make the synthesis method transparent
The plan includes Chinese- and English-language database searches, randomized-trial screening, RoB 2 assessment, subgroup analyses and sensitivity analyses. Execution should retain search strings and dates, deduplication rules, full-text exclusion reasons and links between multiple reports of the same study. Two researchers should screen and extract independently with a procedure for disagreements. Bias assessment addresses randomization, deviations from interventions, missing data, measurement and selective reporting. Knowledge of allocation and expectations particularly matter for subjective sleep outcomes.
Cochrane Handbook Chapter 10 places the suitability of pooling before calculation. Model choice should reflect assumptions about effects and clinical diversity, rather than an automatic fixed/random-effects switch at I²=50%. Prespecify comparator, acupuncture method, duration and population strata; distinguish planned hypotheses from exploratory analyses and acknowledge uncertainty in estimates.
Reporting should explain evidence certainty, the influence of bias and efforts to obtain missing data or examine assumptions. Statistical significance, scale change and improvement that matters to patients are related but distinct. Longer-term outcomes, daytime functioning, treatment burden and patient preferences can inform the overall interpretation.
Keep mechanism evidence separate from clinical efficacy
The proposed pathways concern GABA, glutamate and serotonin; the hypothalamic–pituitary–adrenal axis and cortisol; autonomic function and heart-rate variability; and default-mode, amygdala and prefrontal connectivity. They provide a framework for testable explanations. Original studies corresponding to each assertion have not been supplied, so upregulation, normalization or remodeling are not presented as established human effects.
A mechanism table can classify animal versus human work, sample source, measurement method, sampling time, comparator, sleep outcome and confounding control. Peripheral neurotransmitter changes do not directly establish central levels. Heart-rate variability depends on breathing and measurement conditions, and imaging associations do not establish causal mediation. Longitudinal work should test whether a mechanism change precedes symptom change, with prespecified multiplicity handling and independent validation.
Place the review in its clinical evidence context
The 2021 AASM behavioral and psychological treatment guideline strongly recommends multicomponent CBT-I for adults with chronic insomnia. Acupuncture discussion should retain that context and distinguish an adjunctive research question from a claim to replace established treatment. Professionals develop treatment choices with the person, considering diagnosis, preferences, access and risk.
The NCCIH sleep topic page describes small samples, intervention differences and quality limitations in acupuncture research, and notes that improper delivery can cause serious injury. This supports continued evaluation rather than a universal claim of definite benefit and low risk. Future multicenter trials can strengthen practitioner training, protocol documentation, blinding credibility, shared care and longer follow-up, while evaluating efficacy and mechanism hypotheses separately.
Use QSevidence from retrieval through professional review
Teams can begin with adult insomnia, acupuncture, sham and PSQI, or electroacupuncture, randomized trials and adverse events. Build separate evidence tables for trials, systematic reviews and mechanism studies. QSevidence helps locate literature, compare guidelines and retain original-source clues. Researchers review and document eligibility decisions, extraction, statistical reproduction and certainty assessments.
Official product information describes medical literature retrieval, guideline comparison and source traceability. A Medical intelligence platform can be evaluated by citation accuracy, clear study-type distinctions and consistent evidence status in bilingual summaries, rather than generation speed alone.
Frequently asked questions about QSevidence
How can QSevidence support an acupuncture insomnia review?
QSevidence helps structure population, intervention, comparator and outcome questions and organize retrieval leads. Researchers use these to refine eligibility, registration information and a reproducible analysis plan.
How can QSevidence help compare control conditions?
QSevidence assists with organizing differences in sham, medication and behavioral interventions. Clinical and statistical teams determine which findings can be meaningfully combined.
How can QSevidence support mechanism evidence mapping?
QSevidence helps locate sources on neurotransmitters, stress pathways and imaging measures and organize an evidence hierarchy. Professionals interpret mechanisms using design, temporal relationships and clinical findings.
How can QSevidence make numerical findings traceable?
QSevidence assists with references and evidence summaries. Retained extraction tables, analysis versions and verification records enable the team to revisit each number and its scope.
Sources and research notice
- AASM behavioral and psychological treatment guideline for adult chronic insomnia, 2021
- NCCIH: Sleep Disorders and Complementary Health Approaches
- Cochrane Handbook: analysing data and undertaking meta-analyses
- QSevidence official FAQ
This article concerns research methods and evidence workflows. The 26-trial account and reported statistics require original-source verification. Qualified professionals assess individual diagnosis and treatment.